Piccinini Laura

SEC source: 0001140361-26-029636 · form4.xml · derivative · entry 3

Piccinini Laura · CIK 0001875140 · SVP International

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 28,336 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: On July 19, 2023, the reporting person received a target grant of 28,336 performance share units. Between 0% and 200% of the target number was to be earned based on achievement of pre-determined performance metrics for fiscal years 2024, 2025 and 2026 as determined by the compensation committee. In addition, 20% of the total shares earned could be awarded (or cancelled) based on total shareholder return relative to a peer group of companies over a three-year performance period in accordance with performance metrics. Based on performance over the period, 8,047 shares of Common Stock were issued to the reporting person under this grant and the remaining shares were forfeited.

F3 · derivative.exercise_date: On July 19, 2023, the reporting person received a target grant of 28,336 performance share units. Between 0% and 200% of the target number was to be earned based on achievement of pre-determined performance metrics for fiscal years 2024, 2025 and 2026 as determined by the compensation committee. In addition, 20% of the total shares earned could be awarded (or cancelled) based on total shareholder return relative to a peer group of companies over a three-year performance period in accordance with performance metrics. Based on performance over the period, 8,047 shares of Common Stock were issued to the reporting person under this grant and the remaining shares were forfeited.

F3 · derivative.expiration_date: On July 19, 2023, the reporting person received a target grant of 28,336 performance share units. Between 0% and 200% of the target number was to be earned based on achievement of pre-determined performance metrics for fiscal years 2024, 2025 and 2026 as determined by the compensation committee. In addition, 20% of the total shares earned could be awarded (or cancelled) based on total shareholder return relative to a peer group of companies over a three-year performance period in accordance with performance metrics. Based on performance over the period, 8,047 shares of Common Stock were issued to the reporting person under this grant and the remaining shares were forfeited.

SEC source: 0001140361-26-029636 · form4.xml · nonDerivative · entry 2

Piccinini Laura · CIK 0001875140 · SVP International

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 81,929

F2 · shares: The exempt disposition of 4,506 shares of Common Stock of AngioDynamics was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying performance share units granted to the reporting person on July 19, 2023.

SEC source: 0001140361-26-029636 · form4.xml · nonDerivative · entry 1

Piccinini Laura · CIK 0001875140 · SVP International

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 86,435

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: This acquisition of 8,047 shares of Common Stock ("Common Stock") of AngioDynamics, Inc. ("AngioDynamics") represents shares acquired through the vesting and settlement of performance share units granted to the reporting person on July 19, 2023.

SEC source: 0001140361-26-029185 · form4.xml · nonDerivative · entry 3

Piccinini Laura · CIK 0001875140 · SVP International

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 58,528

F3 · shares: The exempt disposition of 616 shares of common stock of AngioDynamics was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying restricted stock units granted to the reporting person on July 20, 2022.

SEC source: 0001140361-26-029185 · form4.xml · nonDerivative · entry 2

Piccinini Laura · CIK 0001875140 · SVP International

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 59,144

F2 · shares: The exempt disposition of 3,074 shares of common stock of AngioDynamics was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying restricted stock units granted to the reporting person on July 17, 2024.

SEC source: 0001140361-26-029185 · form4.xml · nonDerivative · entry 1

Piccinini Laura · CIK 0001875140 · SVP International

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 62,218

F1 · shares: The exempt disposition of 4,538 shares of common stock of AngioDynamics, Inc. ("AngioDynamics") was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying restricted stock units granted to the reporting person on July 16, 2025.

SEC source: 0001140361-26-029333 · form4.xml · derivative · entry 2

Piccinini Laura · CIK 0001875140 · SVP International

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 19,860

Underlying: Common Stock · 19,860 shares

Expires not disclosed

F2 · derivative.exercise_price: Each performance right represents a contingent right to receive one share of Common Stock. The target number of shares of Common Stock is set forth in columns 5 and 7 of Table II. Between 0% and 200% of the target number will be earned based on total shareholder return relative to a peer group of companies over a three-year performance period (with a potential upward or downward 20% adjustment on the calculated achievement based on total shareholder return relative to a peer group of companies over a three-year performance period (for a total potential payout of up to 240% of the target number in the aggregate)) in accordance with performance metrics as determined by the compensation committee. Any shares that do not vest at the end of the performance period will be forfeited.

F2 · derivative.exercise_date: Each performance right represents a contingent right to receive one share of Common Stock. The target number of shares of Common Stock is set forth in columns 5 and 7 of Table II. Between 0% and 200% of the target number will be earned based on total shareholder return relative to a peer group of companies over a three-year performance period (with a potential upward or downward 20% adjustment on the calculated achievement based on total shareholder return relative to a peer group of companies over a three-year performance period (for a total potential payout of up to 240% of the target number in the aggregate)) in accordance with performance metrics as determined by the compensation committee. Any shares that do not vest at the end of the performance period will be forfeited.

F2 · derivative.expiration_date: Each performance right represents a contingent right to receive one share of Common Stock. The target number of shares of Common Stock is set forth in columns 5 and 7 of Table II. Between 0% and 200% of the target number will be earned based on total shareholder return relative to a peer group of companies over a three-year performance period (with a potential upward or downward 20% adjustment on the calculated achievement based on total shareholder return relative to a peer group of companies over a three-year performance period (for a total potential payout of up to 240% of the target number in the aggregate)) in accordance with performance metrics as determined by the compensation committee. Any shares that do not vest at the end of the performance period will be forfeited.

SEC source: 0001140361-26-029333 · form4.xml · nonDerivative · entry 1

Piccinini Laura · CIK 0001875140 · SVP International

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 78,388

F1 · shares: The acquisition of 19,860 shares of common stock ("Common Stock") of AngioDynamics, Inc. represents 19,860 restricted stock units, each of which represents a contingent right to receive one share of Common Stock. These restricted stock units vest in four equal annual installments beginning on July 15, 2027, such that 25% of the restricted stock units will vest on each of July 15, 2027, 2028, 2029 and 2030.

SEC source: 0001140361-25-026799 · form4.xml · nonDerivative · entry 2

Piccinini Laura · CIK 0001875140 · SVP International

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 66,756

F2 · shares: The exempt disposition of 616 shares of common stock of AngioDynamics was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying restricted stock units granted to the reporting person on July 20, 2022.

SEC source: 0001140361-25-026799 · form4.xml · nonDerivative · entry 1

Piccinini Laura · CIK 0001875140 · SVP International

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 67,372

F1 · shares: The exempt disposition of 1,983 shares of common stock of AngioDynamics, Inc. ("AngioDynamics") was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying restricted stock units granted to the reporting person on July 19, 2023.

SEC source: 0001140361-25-026633 · form4.xml · nonDerivative · entry 1

Piccinini Laura · CIK 0001875140 · SVP International

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 69,355

F1 · shares: The exempt disposition of 3,074 shares of common stock of AngioDynamics, Inc. was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying restricted stock units granted to the reporting person on July 17, 2024

SEC source: 0001140361-25-026466 · form4.xml · derivative · entry 2

Piccinini Laura · CIK 0001875140 · SVP International

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 32,423

Underlying: Common Stock · 32,423 shares

Expires not disclosed

F2 · derivative.exercise_price: Each performance right represents a contingent right to receive one share of Common Stock. The target number of shares of Common Stock is set forth in columns 5 and 7 of Table II. Between 0% and 200% of the target number will be earned based on total shareholder return relative to a peer group of companies over a three-year performance period (with a potential upward or downward 20% adjustment on the calculated achievement based on total shareholder return relative to a peer group of companies over a three-year performance period (for a total potential payout of up to 240% of the target number in the aggregate)) in accordance with performance metrics as determined by the compensation committee. Any shares that do not vest at the end of the performance period will be forfeited.

F2 · derivative.exercise_date: Each performance right represents a contingent right to receive one share of Common Stock. The target number of shares of Common Stock is set forth in columns 5 and 7 of Table II. Between 0% and 200% of the target number will be earned based on total shareholder return relative to a peer group of companies over a three-year performance period (with a potential upward or downward 20% adjustment on the calculated achievement based on total shareholder return relative to a peer group of companies over a three-year performance period (for a total potential payout of up to 240% of the target number in the aggregate)) in accordance with performance metrics as determined by the compensation committee. Any shares that do not vest at the end of the performance period will be forfeited.

F2 · derivative.expiration_date: Each performance right represents a contingent right to receive one share of Common Stock. The target number of shares of Common Stock is set forth in columns 5 and 7 of Table II. Between 0% and 200% of the target number will be earned based on total shareholder return relative to a peer group of companies over a three-year performance period (with a potential upward or downward 20% adjustment on the calculated achievement based on total shareholder return relative to a peer group of companies over a three-year performance period (for a total potential payout of up to 240% of the target number in the aggregate)) in accordance with performance metrics as determined by the compensation committee. Any shares that do not vest at the end of the performance period will be forfeited.

SEC source: 0001140361-25-026466 · form4.xml · nonDerivative · entry 1

Piccinini Laura · CIK 0001875140 · SVP International

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 72,429

F1 · shares: The acquisition of 32,423 shares of common stock ("Common Stock") of AngioDynamics, Inc. represents 32,423 restricted stock units, each of which represents a contingent right to receive one share of Common Stock. These restricted stock units vest in four equal annual installments beginning on July 16, 2026, such that 25% of the restricted stock units will vest on each of July 16, 2026, 2027, 2028 and 2029.

SEC source: 0001140361-24-034271 · form4.xml · nonDerivative · entry 2

Piccinini Laura · CIK 0001875140 · SVP International

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 38,052

F2 · shares: The exempt disposition of 413 shares of common stock of AngioDynamics was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares of underlying restricted stock units granted to the reporting person on July 21, 2021.

SEC source: 0001140361-24-034271 · form4.xml · nonDerivative · entry 1

Piccinini Laura · CIK 0001875140 · SVP International

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 38,465

F1 · shares: The exempt disposition of 616 shares of common stock of AngioDynamics, Inc. ("AngioDynamics") was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying restricted stock units granted to the reporting person on July 20, 2022.

SEC source: 0001140361-24-033786 · form4.xml · nonDerivative · entry 1

Piccinini Laura · CIK 0001875140 · SVP International

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 39,081

F1 · shares: The exempt disposition of 1,983 shares of common stock of AngioDynamics, Inc. was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying restricted stock units granted to the reporting person on July 19, 2023.

SEC source: 0001140361-24-033638 · form4.xml · derivative · entry 3

Piccinini Laura · CIK 0001875140 · SVP International

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 29,863

Underlying: Common Stock · 29,863 shares

Expires 2034-07-17

F3 · derivative.exercise_date: These stock options vest in four equal annual installments beginning on July 17, 2025, such that 25% of the options will vest on each of July 17, 2025, 2026, 2027 and 2028.

SEC source: 0001140361-24-033638 · form4.xml · derivative · entry 2

Piccinini Laura · CIK 0001875140 · SVP International

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 30,428

Underlying: Common Stock · 30,428 shares

Expires not disclosed

F2 · derivative.exercise_price: Each performance right represents a contingent right to receive one share of Common Stock. The target number of shares of Common Stock is set forth in columns 5 and 7 of Table II. Between 0% and 200% of the target number will be earned based on total shareholder return relative to a peer group of companies over a three-year performance period (with a potential upward or downward 20% adjustment on the calculated achievement based on total shareholder return relative to a peer group of companies over a three-year performance period (for a total potential payout of up to 240% of the target number in the aggregate)) in accordance with performance metrics as determined by the compensation committee. Any shares that do not vest at the end of the performance period will be forfeited.

F2 · derivative.exercise_date: Each performance right represents a contingent right to receive one share of Common Stock. The target number of shares of Common Stock is set forth in columns 5 and 7 of Table II. Between 0% and 200% of the target number will be earned based on total shareholder return relative to a peer group of companies over a three-year performance period (with a potential upward or downward 20% adjustment on the calculated achievement based on total shareholder return relative to a peer group of companies over a three-year performance period (for a total potential payout of up to 240% of the target number in the aggregate)) in accordance with performance metrics as determined by the compensation committee. Any shares that do not vest at the end of the performance period will be forfeited.

F2 · derivative.expiration_date: Each performance right represents a contingent right to receive one share of Common Stock. The target number of shares of Common Stock is set forth in columns 5 and 7 of Table II. Between 0% and 200% of the target number will be earned based on total shareholder return relative to a peer group of companies over a three-year performance period (with a potential upward or downward 20% adjustment on the calculated achievement based on total shareholder return relative to a peer group of companies over a three-year performance period (for a total potential payout of up to 240% of the target number in the aggregate)) in accordance with performance metrics as determined by the compensation committee. Any shares that do not vest at the end of the performance period will be forfeited.

SEC source: 0001140361-24-033638 · form4.xml · nonDerivative · entry 1

Piccinini Laura · CIK 0001875140 · SVP International

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 41,064

F1 · shares: The acquisition of 21,971 shares of common stock ("Common Stock") of AngioDynamics, Inc. represents 21,971 restricted stock units, each of which represents a contingent right to receive one share of Common Stock. These restricted stock units vest in four equal annual installments beginning on July 17, 2025, such that 25% of the restricted stock units will vest on each of July 17, 2025, 2026, 2027 and 2028.

SEC source: 0001140361-24-035601 · form4.xml · derivative · entry 3

Piccinini Laura · CIK 0001875140 · SVP International

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 5,903 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: On July 21, 2021, the reporting person received a target grant of 5,903 performance share units. Between 0% and 200% of the target number was to be earned based on achievement of pre-determined performance metrics for fiscal years 2022, 2023 and 2024 as determined by the compensation committee. In addition, 20% of the total shares earned could be awarded (or cancelled) based on total shareholder return relative to a peer group of companies over a three-year performance period in accordance with performance metrics. Based on performance over the period, 4,439 shares of Common Stock were issued to the reporting person under this grant and the remaining shares were forfeited.

F3 · derivative.exercise_date: On July 21, 2021, the reporting person received a target grant of 5,903 performance share units. Between 0% and 200% of the target number was to be earned based on achievement of pre-determined performance metrics for fiscal years 2022, 2023 and 2024 as determined by the compensation committee. In addition, 20% of the total shares earned could be awarded (or cancelled) based on total shareholder return relative to a peer group of companies over a three-year performance period in accordance with performance metrics. Based on performance over the period, 4,439 shares of Common Stock were issued to the reporting person under this grant and the remaining shares were forfeited.

F3 · derivative.expiration_date: On July 21, 2021, the reporting person received a target grant of 5,903 performance share units. Between 0% and 200% of the target number was to be earned based on achievement of pre-determined performance metrics for fiscal years 2022, 2023 and 2024 as determined by the compensation committee. In addition, 20% of the total shares earned could be awarded (or cancelled) based on total shareholder return relative to a peer group of companies over a three-year performance period in accordance with performance metrics. Based on performance over the period, 4,439 shares of Common Stock were issued to the reporting person under this grant and the remaining shares were forfeited.

SEC source: 0001140361-24-035601 · form4.xml · nonDerivative · entry 2

Piccinini Laura · CIK 0001875140 · SVP International

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 40,006

F2 · shares: The exempt disposition of 2,485 shares of Common Stock of AngioDynamics was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying performance share units granted to the reporting person on July 21, 2021.

SEC source: 0001140361-24-035601 · form4.xml · nonDerivative · entry 1

Piccinini Laura · CIK 0001875140 · SVP International

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 42,491

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: This acquisition of 4,439 shares of Common Stock ("Common Stock") of AngioDynamics, Inc. ("AngioDynamics") represents shares acquired through the vesting and settlement of performance share units granted to the reporting person on July 21, 2021.

SEC source: 0001140361-23-036117 · form4.xml · nonDerivative · entry 2

Piccinini Laura · CIK 0001875140 · SVP International

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 19,093

F2 · shares: The exempt disposition of 413 shares of common stock of AngioDynamics was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying restricted stock units granted to the reporting person on July 21, 2021.

SEC source: 0001140361-23-036117 · form4.xml · nonDerivative · entry 1

Piccinini Laura · CIK 0001875140 · SVP International

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 19,506

F1 · shares: The exempt disposition of 616 shares of common stock of AngioDynamics, Inc. ("AngioDynamics") was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying restricted stock units granted to the reporting person on July 20, 2022.

SEC source: 0001140361-23-035728 · form4.xml · derivative · entry 3

Piccinini Laura · CIK 0001875140 · SVP International

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 29,322

Underlying: Common Stock · 29,322 shares

Expires 2033-07-19

F3 · derivative.exercise_date: These stock options vest in four equal annual installments beginning on July 19, 2024, such that 25% of the options will vest on each of July 19, 2024, 2025, 2026 and 2027.

SEC source: 0001140361-23-035728 · form4.xml · derivative · entry 2

Piccinini Laura · CIK 0001875140 · SVP International

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 28,336

Underlying: Common Stock · 28,336 shares

Expires not disclosed

F2 · derivative.exercise_price: Each performance right represents a contingent right to receive one share of Common Stock. The target number of shares of Common Stock is set forth in columns 5 and 7 of Table II. Between 0% and 200% of the target number will be earned over a three-year performance period in accordance with performance metrics as determined by the compensation committee (with a potential upward or downward 20% adjustment on the calculated achievement based on total shareholder return relative to a peer group of companies over a three-year performance period (for a total potential payout of up to 240% of the target number in the aggregate)). Any shares that do not vest at the end of the performance period will be forfeited.

F2 · derivative.exercise_date: Each performance right represents a contingent right to receive one share of Common Stock. The target number of shares of Common Stock is set forth in columns 5 and 7 of Table II. Between 0% and 200% of the target number will be earned over a three-year performance period in accordance with performance metrics as determined by the compensation committee (with a potential upward or downward 20% adjustment on the calculated achievement based on total shareholder return relative to a peer group of companies over a three-year performance period (for a total potential payout of up to 240% of the target number in the aggregate)). Any shares that do not vest at the end of the performance period will be forfeited.

F2 · derivative.expiration_date: Each performance right represents a contingent right to receive one share of Common Stock. The target number of shares of Common Stock is set forth in columns 5 and 7 of Table II. Between 0% and 200% of the target number will be earned over a three-year performance period in accordance with performance metrics as determined by the compensation committee (with a potential upward or downward 20% adjustment on the calculated achievement based on total shareholder return relative to a peer group of companies over a three-year performance period (for a total potential payout of up to 240% of the target number in the aggregate)). Any shares that do not vest at the end of the performance period will be forfeited.

SEC source: 0001140361-23-035728 · form4.xml · nonDerivative · entry 1

Piccinini Laura · CIK 0001875140 · SVP International

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 20,122

F1 · shares: The acquisition of 14,168 shares of common stock ("Common Stock") of AngioDynamics, Inc. represents 14,168 restricted stock units, each of which represents a contingent right to receive one share of Common Stock. These restricted stock units vest in four equal annual installments beginning on July 19, 2024, such that 25% of the restricted stock units will vest on each of July 19, 2024, 2025, 2026 and 2027.

SEC source: 0001140361-23-028006 · form4.xml · nonDerivative · entry 1

Piccinini Laura · CIK 0001875140 · SVP International

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,954

F1 · shares: The exempt disposition of 1,400 shares of common stock of AngioDynamics, Inc. was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying restricted stock units granted to the reporting person on June 1, 2021.

SEC source: 0001567619-22-014371 · doc1.xml · derivative · entry 3

Piccinini Laura · CIK 0001875140 · SVP International

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,312

Underlying: Common Stock · 10,312 shares

Expires 2032-07-20

F3 · derivative.exercise_date: These stock options vest in four equal annual installments beginning on July 20, 2023, such that 25% of the options will vest on each of July 20, 2023, 2024, 2025 and 2026.

SEC source: 0001567619-22-014371 · doc1.xml · derivative · entry 2

Piccinini Laura · CIK 0001875140 · SVP International

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,803

Underlying: Common Stock · 8,803 shares

Expires not disclosed

F2 · derivative.exercise_price: Each performance right represents a contingent right to receive one share of Common Stock. The target number of shares of Common Stock is set forth in columns 5 and 7 of Table II. Between 0% and 200% of the target number will be earned based on total shareholder return relative to a peer group of companies over a three-year performance period (with a potential upward or downward 20% adjustment on the calculated achievement based on total shareholder return relative to a peer group of companies over a three-year performance period (for a total potential payout of up to 240% of the target number in the aggregate)) in accordance with performance metrics as determined by the compensation committee. Any shares that do not vest at the end of the performance period will be forfeited.

F2 · derivative.exercise_date: Each performance right represents a contingent right to receive one share of Common Stock. The target number of shares of Common Stock is set forth in columns 5 and 7 of Table II. Between 0% and 200% of the target number will be earned based on total shareholder return relative to a peer group of companies over a three-year performance period (with a potential upward or downward 20% adjustment on the calculated achievement based on total shareholder return relative to a peer group of companies over a three-year performance period (for a total potential payout of up to 240% of the target number in the aggregate)) in accordance with performance metrics as determined by the compensation committee. Any shares that do not vest at the end of the performance period will be forfeited.

F2 · derivative.expiration_date: Each performance right represents a contingent right to receive one share of Common Stock. The target number of shares of Common Stock is set forth in columns 5 and 7 of Table II. Between 0% and 200% of the target number will be earned based on total shareholder return relative to a peer group of companies over a three-year performance period (with a potential upward or downward 20% adjustment on the calculated achievement based on total shareholder return relative to a peer group of companies over a three-year performance period (for a total potential payout of up to 240% of the target number in the aggregate)) in accordance with performance metrics as determined by the compensation committee. Any shares that do not vest at the end of the performance period will be forfeited.

SEC source: 0001567619-22-014371 · doc1.xml · nonDerivative · entry 1

Piccinini Laura · CIK 0001875140 · SVP International

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,354

F1 · shares: The acquisition of 4,402 shares of common stock ("Common Stock") of AngioDynamics, Inc. represents 4,402 restricted stock units, each of which represents a contingent right to receive one share of Common Stock. These restricted stock units vest in four equal annual installments beginning on July 20, 2023, such that 25% of the restricted stock units will vest on each of July 20, 2023, 2024, 2025 and 2026.

SEC source: 0001567619-21-018541 · doc1.xml · derivative · entry 3

Piccinini Laura · CIK 0001875140 · SVP International

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,019

Underlying: Common Stock · 8,019 shares

Expires 2031-07-21

F1 · date: The restricted stock units, performance rights and stock options set forth in this Form 4 were granted to the Reporting Person effective July 21, 2021. Due to an administrative error, the acquisition of the securities by the Reporting Person was delayed.

F4 · derivative.exercise_date: These stock options vest in four equal annual installments beginning on July 21, 2022, such that 25% of the options will vest on each of July 21, 2022, 2023, 2024 and 2025.

SEC source: 0001567619-21-018541 · doc1.xml · derivative · entry 2

Piccinini Laura · CIK 0001875140 · SVP International

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,903

Underlying: Common Stock · 5,903 shares

Expires not disclosed

F3 · derivative.exercise_price: Each performance right represents a contingent right to receive one share of Common Stock. The target number of shares of Common Stock is set forth in columns 5 and 7 of Table II. Between 0% and 200% of the target number will be earned based on total shareholder return relative to a peer group of companies over a three-year performance period (with a potential upward or downward 20% adjustment on the calculated achievement based on total shareholder return relative to a peer group of companies over a three-year performance period (for a total potential payout of up to 240% of the target number in the aggregate)) in accordance with performance metrics as determined by the compensation committee. Any shares that do not vest at the end of the performance period will be forfeited.

F1 · date: The restricted stock units, performance rights and stock options set forth in this Form 4 were granted to the Reporting Person effective July 21, 2021. Due to an administrative error, the acquisition of the securities by the Reporting Person was delayed.

F3 · derivative.exercise_date: Each performance right represents a contingent right to receive one share of Common Stock. The target number of shares of Common Stock is set forth in columns 5 and 7 of Table II. Between 0% and 200% of the target number will be earned based on total shareholder return relative to a peer group of companies over a three-year performance period (with a potential upward or downward 20% adjustment on the calculated achievement based on total shareholder return relative to a peer group of companies over a three-year performance period (for a total potential payout of up to 240% of the target number in the aggregate)) in accordance with performance metrics as determined by the compensation committee. Any shares that do not vest at the end of the performance period will be forfeited.

F3 · derivative.expiration_date: Each performance right represents a contingent right to receive one share of Common Stock. The target number of shares of Common Stock is set forth in columns 5 and 7 of Table II. Between 0% and 200% of the target number will be earned based on total shareholder return relative to a peer group of companies over a three-year performance period (with a potential upward or downward 20% adjustment on the calculated achievement based on total shareholder return relative to a peer group of companies over a three-year performance period (for a total potential payout of up to 240% of the target number in the aggregate)) in accordance with performance metrics as determined by the compensation committee. Any shares that do not vest at the end of the performance period will be forfeited.

SEC source: 0001567619-21-018541 · doc1.xml · nonDerivative · entry 1

Piccinini Laura · CIK 0001875140 · SVP International

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,952

F1 · date: The restricted stock units, performance rights and stock options set forth in this Form 4 were granted to the Reporting Person effective July 21, 2021. Due to an administrative error, the acquisition of the securities by the Reporting Person was delayed.

F2 · shares: The acquisition of 2,952 shares of common stock ("Common Stock") of AngioDynamics, Inc. represents 2,952 restricted stock units, each of which represents a contingent right to receive one share of Common Stock. These restricted stock units vest in four equal annual installments beginning on July 21, 2022, such that 25% of the restricted stock units will vest on each of July 21, 2022, 2023, 2024 and 2025.